Register Login

Sutro Biopharma Inc (STRO)

  • Event
  • June 16, 2022, 11:00 UTC

(10% Negative) SUTRO BIOPHARMA, INC. (STRO) Announces Delay in opportunities Trials for our management to predict all risks Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 2, 2025, 7:41 a.m.

    📋 SUTRO BIOPHARMA, INC. (STRO) - Clinical Trial Update

    Filing Date: 2022-06-16

    Accepted: 2022-06-16 07:00:30

    Event Type: Clinical Trial Update

    Event Details:

    Sutro Biopharma Inc (STRO) Announces Clinical Trial Update Sutro Biopharma Inc (STRO) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: opportunities, contained
    • Diseases/Conditions: our management to predict all risks, any we may make
    • Clinical Stage: clinical trial
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
    • Collaboration: Company
      • Targeting ADC Potential First and Best-in-Class ADC for B-Cell Malignancies STRO 001 Potential First-in-Class Molecule for Patients with NHL and MM Stable CD74 targeting ADC for hematological cancers designed to minimize bystander effects CD74 STRO 001 CD74 pAMF F404 Non-cleavable linker Maytansinoid warhead STRO-001 is a homogeneous antibody drug conjugate (ADC) with a drug-antibody ratio (DAR) of 2, targeting CD74: CD74 is expressed in many hematological cancers and rapidly internalized Conjugation through precisely positioned non-natural amino acids. p-azidomethyl-L- phenylalanine, at positions F404 on the heavy chain Comprises two non-cleavable linker-warheads that are stable in circulation The active catabolite, Maytansinoid derivative, efficiently kills tumor cells following internalization of the ADC and was designed to minimize bystander effects STRO-001-BCM1 Study Design and Updates Ongoing Phase 1 dose escalation study with NHL update at ASH 2020
      • targeting of cytotoxic payloads Bispecific ADC ISAC: Immune- stimulating ADC: targeting novel payloads Bispecific Antibody Tumor or Stromal Antigen Immune Cell Engager Optimized format and affinity Improved specificity for optimized therapeutic window Tumor Antigen Dual Tumor Antigens Conjugated Antibody ADC or ISAC iADC Tumor Antigen Site-specific dual drug conjugate with complementary modalities (TME modulator +/- immune modulator) Immune Cell Engager Modality Drug Properties Target Structure Cytokine Derivative Prodrug cytokine targeting functional cytokine to tumor Prodrug Cytokine Derivative Tumor Selective Mask Releasable mask cytokine Robust Pipeline through Wholly-Owned and Partnered Programs Five product candidates advancing in the clinic and late-stage discovery programs Modality Program Target Indication Discovery Preclinical Phase 1/1b Phase 2/3 Partner Antibody-Drug Conjugate STRO-002 FolRα ADC Ovarian Cancer Ovarian Cancer (bevacizumab combo) Endometrial Cancer NSCLC/Non-Gyn Cancers STRO-001 CD74 ADC Lymphomas Multiple Myeloma CC-9971
      • planned for ~15 patients FPI December 2021

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Sutro Biopharma Inc
    • CIK: 0001382101
    • Ticker Symbol: STRO
    • Period End Date: 2022-06-16
    • Document Type: 8-K

Search

News categories